Recently, the FDA has granted orphan drug status to GedeptinTM (adenoviral vector-expressing E. coli PNP gene), that works efficiently with a broad range of nucleoside prodrugs generating active metabolites with high anti-tumor activity for treatment of anatomically accessible oral and pharyngeal cancers. The gene discussed is PNP; the disease is neoplasm.